TIRZ 5mg

Description

TIRZ 5mg

Thirzepatide is an antidiabetic peptide used to treat type 2 diabetes and to promote weight loss. It is administered by subcutaneous injection. Thirzepatide acts on two types of receptors: GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide). Both of these hormones are involved in blood sugar control and are secreted by intestinal cells after food consumption, leading to insulin secretion. Thiopatide as a long-acting GIP analog activates both of these receptors, leading to improved glycemic control【14†source】.

It increases tissue sensitivity to insulin and enhances its secretion by pancreatic beta cells, which contributes to lowering blood glucose levels during fasting and after meals. Thirzepatide also delays gastric emptying, which reduces glucose absorption from meals, reduces appetite and increases satiety, leading to weight and fat reduction【12†source】..

TIRZ 5mg: Tirzepatide differs from semaglutide, another drug for type 2 diabetes and obesity, in that it also mimics the hormone GIP, which affects not only the delay of gastric emptying and appetite, but also the way fat is deposited in the body【13†source】.

It was approved by the FDA (U.S. Food and Drug Administration) for the treatment of type 2 diabetes in May 2022. Studies have shown that tirzepatide can help people lose an average of 27% of their body weight in a year and a half when used in conjunction with diet and exercise【13†source】. Tirzepatide (TIRZ 5mg) is indicated to improve blood sugar control in adults with type 2 diabetes as an adjunct to diet and exercise, as well as to support weight management with a calorie-restricted diet and increased physical activity【14†source】.

The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for marketing in the European Union, and can only be used for scientific research.